文献速递血管炎

用于血管影像学的新兴PET放射性示踪剂

Emerging PET radiotracers for vascular imaging.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

本聚焦综述讨论用于大血管血管炎(LVV)血管炎症成像的多种新兴PET放射性示踪剂。文章指出18F-FDG虽对LVV有较好诊断准确性,但可被血管壁所有葡萄糖代谢细胞摄取而出现非特异性动脉摄取;许多最初为肿瘤学或动脉粥样硬化成像开发的靶向单核/巨噬细胞、T和B淋巴细胞等炎症细胞的示踪剂可能提供有用的疾病活动度指标。

要点

  • 18F-FDG对LVV有较好诊断准确性,但可被血管壁所有葡萄糖代谢细胞摄取,出现与炎症活动无关的非特异性动脉摄取。
  • 延迟显像方案和定量参数成像等PET技术方法有望提高18F-FDG在LVV中的诊断准确性。
  • 临床需要靶向特定免疫细胞和炎症过程的新PET示踪剂,以指导LVV的个体化治疗。

核心结论

  • 临床确实需要靶向特定免疫细胞和炎症过程的新PET示踪剂,以了解LVV的潜在疾病病理并指导个体化治疗。
  • 许多最初为肿瘤学或动脉粥样硬化成像开发的新兴PET示踪剂可能为LVV提供有用的疾病活动度指标。

研究设计与样本

  • 本文为聚焦综述,讨论用于血管炎症成像的多种最有前景的新兴PET放射性核素示踪剂。

主要发现

  • 18F-FDG对LVV具有较好的诊断准确性。
  • 18F-FDG可被血管壁所有葡萄糖代谢细胞摄取,因此患者尽管对治疗有良好临床反应,仍可出现常与炎症疾病活动无关的非特异性动脉摄取。
  • 延迟显像方案和定量参数成像等PET成像技术与方法的进展有可能提高18F-FDG在LVV中的诊断准确性。
  • 许多最初为肿瘤学或动脉粥样硬化成像开发的新兴PET示踪剂可能提供有用的LVV疾病活动度指标,包括靶向单核细胞/巨噬细胞、T和B淋巴细胞及其他参与该病发病机制的炎症细胞受体的示踪剂。

临床怎么用

  • 影像学在LVV患者的临床管理中起重要作用,既用于初次就诊时确认诊断,也用于识别已确诊患者的疾病复发。
  • PET成像相对于其他无创成像方式的最大优势在于能够使用靶向放射性核素探针定位和追踪细胞通路,从而在体内评估疾病活动度。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Imaging plays an important role in the clinical management of patients with large-vessel vasculitis (LVV), both to confirm the diagnosis at the time of initial presentation and to identify disease relapses in individuals with established disease. The big advantage of PET imaging over other non-invasive imaging modalities is the ability to employ targeted radionuclide probes to localize and track cellular pathways, providing in vivo assessments of disease activity. While 18F-fluorodeoxyglucose (FDG) has good diagnostic accuracy for LVV, this tracer is taken up by all glucose metabolizing cells in the vessel wall and so non-specific arterial uptake that is often unrelated to inflammatory disease activity can occur in patients despite a good clinical response to treatment. Advances in PET imaging technology and methods such as delayed imaging protocols and quantitative parametric imaging have the potential to improve the diagnostic accuracy of 18F-FDG in LVV. However, there is nevertheless a real clinical need for new PET tracers that target specific immune cells and inflammatory processes to inform about underlying disease pathology and guide individualized treatments for LVV. Many emerging PET tracers developed initially for oncology or atherosclerosis imaging could provide useful measures of disease activity in LVV, including tracers targeted to receptors on monocytes/macrophages, T and B lymphocytes and other inflammatory cells implicated in the pathogenesis of the disease. This focused review will discuss several of the most promising emerging PET radionuclide tracers for imaging vascular inflammation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Peverelli M, Tarkin JM. Emerging PET radiotracers for vascular imaging. Rheumatology (Oxford). 2025. PMID: 40071433. doi:10.1093/rheumatology/keae635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。